16 related articles for article (PubMed ID: 38745179)
1. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma.
Hu Y; Luo Z; Cai S; Xie Q; Zheng S
Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342
[TBL] [Abstract][Full Text] [Related]
2. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma.
Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J
J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968
[TBL] [Abstract][Full Text] [Related]
3. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
4. Ferroptosis in liver cancer: a key role of post-translational modifications.
Xu Y; Xing Z; Abdalla Ibrahim Suliman R; Liu Z; Tang F
Front Immunol; 2024; 15():1375589. PubMed ID: 38650929
[TBL] [Abstract][Full Text] [Related]
5. ARHGAP10, Transcriptionally Regulated by Sodium Butyrate, Promotes Ferroptosis of Ovarian Cancer Cells.
Ke H; Shao J; Hu J; Song X; Han H; Zhu Z; Zhou X; Chen L; Shan Y
Front Biosci (Landmark Ed); 2024 Apr; 29(5):167. PubMed ID: 38812318
[TBL] [Abstract][Full Text] [Related]
6. A new therapeutic perspective: Erastin inhibits tumor progression by driving ferroptosis in myelodysplastic syndromes.
Li J; Ma J; Zhang R; Zhai Y; Zhang W; Fu R
J Investig Med; 2024 Jun; 72(5):414-424. PubMed ID: 38557364
[TBL] [Abstract][Full Text] [Related]
7. Targeting ferroptosis in hepatocellular carcinoma.
Mo Y; Zou Z; Chen E
Hepatol Int; 2024 Feb; 18(1):32-49. PubMed ID: 37880567
[TBL] [Abstract][Full Text] [Related]
8. GPX4 transcriptionally promotes liver cancer metastasis via GRHL3/PTEN/PI3K/AKT axis.
Pan R; Zhao Z; Xu D; Li C; Xia Q
Transl Res; 2024 May; 271():79-92. PubMed ID: 38797432
[TBL] [Abstract][Full Text] [Related]
9. Transformable Supramolecular Self-Assembled Peptides for Cascade Self-Enhanced Ferroptosis Primed Cancer Immunotherapy.
Wang H; Jiao D; Feng D; Liu Q; Huang Y; Hou J; Ding D; Zhang W
Adv Mater; 2024 May; 36(21):e2311733. PubMed ID: 38339920
[TBL] [Abstract][Full Text] [Related]
10. Unveiling the role of APOM gene in liver cancer: Investigating the impact of hsa-miR-4489/MUC1-mediated ferroptosis on the advancement of hepatocellular carcinoma cells.
Liu M; Hu M; Liu R; Wang L; Wang J; Wang Y; Zhang R; Wang H; Liu M; Zhang Y; Wang L; Pei W; Zhang Y
Gene; 2024 May; 925():148591. PubMed ID: 38788818
[TBL] [Abstract][Full Text] [Related]
11. Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma.
Sun G; Liu C; Lu Z; Zhang J; Cao H; Huang T; Dai M; Liu H; Feng T; Tang W; Xia Y
Cancer Cell Int; 2024 May; 24(1):192. PubMed ID: 38822322
[TBL] [Abstract][Full Text] [Related]
12. Remodeling of sorafenib as an orally bioavailable ferroptosis inducer for Lung Cancer by chemical modification of adenine-binding motif.
Kim YJ; Lim B; Kim SY; Shin YZ; Yu N; Shin EK; Lee JE; Jeon YH; Kim DD; Lee J; Cha HJ
Biomed Pharmacother; 2024 May; 176():116758. PubMed ID: 38796972
[TBL] [Abstract][Full Text] [Related]
13. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma.
Li J; Li Y; Wang D; Liao R; Wu Z
J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
